about
Laparoscopic detection and resection of occult liver tumors of multiple cancer types using real-time near-infrared fluorescence guidance.Validation of full-field optical coherence tomography in distinguishing malignant and benign tissue in resected pancreatic cancer specimens.The homeobox gene MEIS1 is methylated in BRAF (p.V600E) mutated colon tumors.Targeted next-generation sequencing of FNA-derived DNA in pancreatic cancer.Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma.In Search for Optimal Targets for Intraoperative Fluorescence Imaging of Peritoneal Metastasis From Colorectal Cancer.SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics.Correlation Between Preoperative Serum Carcinoembryonic Antigen Levels and Expression on Pancreatic and Rectal Cancer Tissue.Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study.Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study.Intraoperative Near-Infrared Fluorescence Imaging of Multiple Pancreatic Neuroendocrine Tumors: A Case Report.Diagnostic value of targeted next-generation sequencing in patients with suspected pancreatic or periampullary cancer.Dilemmas for the pathologist in the oncologic assessment of pancreatoduodenectomy specimens : An overview of different grossing approaches and the relevance of the histopathological characteristics in the oncologic assessment of pancreatoduodenectomThe Dutch Pancreas Biobank Within the Parelsnoer Institute: A Nationwide Biobank of Pancreatic and Periampullary Diseases.CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy.The interferon gamma gene in celiac disease: augmented expression correlates with tissue damage but no evidence for genetic susceptibility.TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.Staging laparoscopy with ultrasound and near-infrared fluorescence imaging to detect occult metastases of pancreatic and periampullary cancerRisk of multiple pancreatic cancers in CDKN2A-p16-Leiden mutation carriersTS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patientsPharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?EUS-guided radiofrequency ablation for a left adrenal oligometastasis of an esophageal adenocarcinomaImage-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent
P50
Q30363788-BB81F041-54D1-4E42-811F-755281CF4F2EQ33570699-D87A98EE-3A26-432F-8FB2-6E14040A1696Q37288532-8BB70B7A-B4F5-4528-85BC-A24817D1274BQ38817331-71D86FFA-B60C-4B1D-B693-A6DF2F07E4C8Q41344580-47563428-3EE9-44F8-8720-060A063B231DQ41560167-741ED8ED-B035-4FCF-9C7A-AB41A6431061Q42075151-ECE73111-BBD2-4ACA-893D-0323D91B8F91Q42255560-0025DF9D-A8E6-408C-A7F3-052F1D960B37Q42954371-9373BABA-8016-4215-B00F-53668ECF5FFDQ48526386-85C5916A-77D8-4068-8C5B-6F2371DDA5CCQ49896980-601CD73F-E8E1-40F2-9818-579A652056F9Q51813843-EFE618DC-167C-4831-93F3-BD120E0D474EQ52339747-356A1611-C250-4325-A691-B6B2CA52020AQ52664723-475938EB-9C0E-452F-BAF9-8597C483CD08Q52722671-35AF52CD-8651-488E-BB64-43DE5414FBBBQ54117909-168A9392-8C10-4415-AA0B-0490B989678EQ54704895-752FF3F8-BC8D-489E-8CE5-5053FD7D4BB9Q55021595-840EC4E0-B471-4313-AF5E-1EDB6CC4154EQ58084995-7A1569B2-FBD6-4931-90B5-83408F720363Q62978088-51777561-9957-40AF-8603-A1ED5EA3FADBQ84239896-D88A7494-3E17-4516-8345-99185E2AD5ADQ85014339-D78AECBE-75E7-456D-88BA-0F556F34A265Q89147711-01AB58A4-06DB-4513-A1E1-A0FF5193FE05Q90553434-EB18716B-7FF5-412B-987B-62269E229934
P50
description
researcher ORCID ID = 0000-0002-6173-592X
@en
wetenschapper
@nl
name
Aranzazu Fariña Sarasqueta
@ast
Aranzazu Fariña Sarasqueta
@en
Aranzazu Fariña Sarasqueta
@nl
type
label
Aranzazu Fariña Sarasqueta
@ast
Aranzazu Fariña Sarasqueta
@en
Aranzazu Fariña Sarasqueta
@nl
altLabel
Aranzazu Farina Sarasqueta
@en
prefLabel
Aranzazu Fariña Sarasqueta
@ast
Aranzazu Fariña Sarasqueta
@en
Aranzazu Fariña Sarasqueta
@nl
P106
P2798
P31
P496
0000-0002-6173-592X